Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers: A Phase I Open-Label Study

By Lasseter K.C.  

Clinical Pharmacokinetics, Vol. 43, Iss. 2, 2004-01 ,pp. : 121-129

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Metrifonate and its Metabolite Dichlorvos in Healthy Volunteers and in Patients with Renal Impairment

By Heinig R.  

Clinical Drug Investigation, Vol. 18, Iss. 1, 1999-07 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

By Weil Angelika  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 607-618

Adis International

Access to resources Recommend Favorite

An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 256-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

By Kadokura Takeshi   Adel Martin   Krauwinkel Walter   Takeshige Tetsuo   Nishida Akito  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 605-609

Springer Publishing Company

Access to resources Recommend Favorite